PETS

171.7

+0.76%↑

PETS

171.7

+0.76%↑

PETS

171.7

+0.76%↑

PETS

171.7

+0.76%↑

PETS

171.7

+0.76%↑

Search

GlaxoSmithKline PLC

Chiusa

SettoreSettore sanitario

1,960.5 1.76

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1909.5

Massimo

1971

Metriche Chiave

By Trading Economics

Entrata

1.2B

1.8B

Vendite

-989M

7.6B

P/E

Media del settore

13.789

49.712

EPS

0.465

Rendimento da dividendi

3.38

Margine di Profitto

24.105

Dipendenti

66,841

EBITDA

577M

2.8B

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+9.56% upside

Dividendi

By Acuity

Rendimento da dividendi

Media del settore

3.38%

2.36%

Utili prossimi

28 lug 2026

Prossima data del Dividendo

9 lug 2026

Prossima data del' Ex Dividendo

13 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-2B

78B

Apertura precedente

1958.74

Chiusura precedente

1960.5

Notizie sul Sentiment di mercato

By Acuity

34%

66%

66 / 342 Classifica in Healthcare

GlaxoSmithKline PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Chi Siamo GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
help-icon Live chat